US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
Time:2024-05-22 01:26:28 Source:travelViews(143)
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Previous:China vows to actively promote restoration of int'l flights
Next:Nina Dobrev hospitalized with a neck brace due to serious e
You may also like
- Hall of Fame outfielder Ken Griffey Jr. to lead Indianapolis 500 field in Corvette pace car
- Israel Gaza: Biden urges Israel to protect Rafah civilians
- Xi Congratulates Pellegrini on Election as President of Slovakia
- 2025 Asian Winter Games to highlight environmental protection, technology
- Christopher Reeve Super/Man documentary
- Feature: Japanese director hopes to show real China to more Japanese people
- Alabama clinics pause IVF treatments after frozen embryo ruling
- Interview: Malaysia pursues holistic strategy to boost Chinese tourist arrivals
- Jennifer Garner visits ex